GM24405
Fibroblast from Skin, Skin
Description:
ULLRICH CONGENITAL MUSCULAR DYSTROPHY; UCMD1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Muscular Dystrophies CMD Specific |
Class |
Congenital Muscle Diseases |
Biopsy Source
|
Skin
|
Cell Type
|
Fibroblast
|
Tissue Type
|
Skin
|
Transformant
|
Untransformed
|
Sample Source
|
Fibroblast from Skin, Skin
|
Race
|
White
|
Ethnicity
|
Not Hispanic/Latino
|
Ethnicity
|
ITALIAN/GERMAN/IRISH/SCOTTISH/ENGLISH/FRENCH
|
Country of Origin
|
USA
|
Family History
|
N
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
PDL at Freeze |
4.45 |
Passage Frozen |
2 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
|
Gene |
COL6A1 |
Chromosomal Location |
21q22.3 |
Allelic Variant 1 |
; ULLRICH CONGENITAL MUSCULAR DYSTROPHY |
Identified Mutation |
957+1G>A |
Remarks |
Clinically affected; mild left thoracic prominence; constipation; achieved and still maintains all of the following without assistance: held up head at 18 months, turned in bed at 18 months, sat at 18 months, stood at 18 months, walked at 2 years, climbed stairs at 30 months, and ran at 2 1/2 years; creatine phosphokinase levels of 509 and 442; muscle biopsy showed abnormal collagen VI on IHC testing; Northstar Assessment Score of 16, previous 6 month Northstar Ambulatory assessment was 17/34; heterozygous for a COL6A1 mutation in exon 12/intron 12, c.957+1G>A, this mutation is likely a splice site mutation. |
Cumulative PDL at Freeze |
4.45 |
Passage Frozen |
2 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
None specified |
Supplement |
- |
|
|